Analyze Diet

Topic:Immune Response

The immune response in horses involves a complex network of cells, tissues, and molecules that work together to protect the animal from pathogens and other harmful agents. This process includes both innate and adaptive immune mechanisms. Innate immunity provides the first line of defense and involves components such as physical barriers, phagocytic cells, and the complement system. Adaptive immunity, on the other hand, is characterized by the activation of lymphocytes and the production of antibodies, which provide a targeted response to specific antigens. Key components of the equine immune system include T cells, B cells, and various cytokines that facilitate communication between immune cells. This page compiles peer-reviewed research studies and scholarly articles that explore the mechanisms, regulation, and implications of immune responses in equine health.
Intraperitoneal and Intracerebral Routes in Serum Protection Tests with the Virus of Equine Encephalomyelitis: I. A Comparison of the Two Routes in Protection Tests.
The Journal of experimental medicine    July 31, 1938   Volume 68, Issue 2 173-189 doi: 10.1084/jem.68.2.173
Olitsky PK, Harford CG.Young (12 to 15 day old) mice are approximately as susceptible to the virus of equine encephalomyelitis, Eastern or Western strain, when it is given intraperitoneally as are adult mice when the virus is injected intracerebrally. With this susceptibility by the intraperitoneal route as a basis, the injection of immune serum-virus mixtures intraperitoneally was found to result in protection in dilutions which give rise to infection after intracerebral inoculation. The difference of protective power by the two indicated routes was shown not to depend on the amount of inoculum nor on the age of th...
The Serum Treatment of Weil’s Disease (Spirochaetosis Icterohaemorrhagica).
The Journal of experimental medicine    November 1, 1916   Volume 24, Issue 5 485-496 doi: 10.1084/jem.24.5.485
Inada R, Ido Y, Hoki R, Ito H, Wani H.Horses immunized with cultures of Spirochaeta icterohaemorrhagiae yield an immune serum having therapeutic properties. With rare exceptions the serum destroys completely the spirochetes contained in the circulating blood. The development of antibodies is promoted by the serum injections. The number of spirochetes in the organs is reduced by the treatment. Secondary manifestations due to the serum are slight and disappear promptly. The ultimate effects of the serum treatment on the symptoms and final outcome of the disease have still to be determined.
Active Immunity Produced by So-Called Balanced or Neutral Mixtures of Diphtheria Toxin and Antitoxin.
The Journal of experimental medicine    March 1, 1909   Volume 11, Issue 2 241-256 doi: 10.1084/jem.11.2.241
Smith T.The foregoing and earlier data taken together demonstrate that an active immunity lasting several years can be produced in guinea-pigs, by the injection of toxin-antitoxin mixtures which have no recognizable harmful effect either immediate or remote. They also show, what might have been anticipated, that under the same conditions mixtures which produce local lesions and which, therefore, contain an excess of toxin produce a much higher degree of immunity than the neutral mixtures, and that an excess of antitoxin reduces the possibility of producing an active immunity, and may extinguish it alt...
Equine Herpesvirus-1 Myeloencephalopathy.
   March 17, 2026  
Although equine herpesvirus myeloencephalopathy (EHM) is a relatively uncommon manifestation of equine herpesvirus-1 (EHV-1) infection, it can cause devastating losses during outbreaks. Antemortem diagnosis of EHM relies mainly on the molecular detection of EHV-1 in nasal secretions and blood. Management of horses affected by EHM is aimed at supportive nursing and nutritional care, at reducing central nervous system inflammation and preventing thromboembolic sequelae. Horses exhibiting sudden and severe neurologic signs consistent with a diagnosis of EHM pose a definite risk to the surrounding...
Research article expression of surfactant protein-A and D, and CD9 in lungs of 1 and 30 day old foals.
   March 17, 2026  
Respiratory diseases are a major cause of morbidity and mortality in the horses of all ages including foals. There is limited understanding of the expression of immune molecules such as tetraspanins and surfactant proteins (SP) and the regulation of the immune responses in the lungs of the foals. Therefore, the expression of CD9, SP-A and SP-D in foal lungs was examined. Results: Lungs from one day old (n = 6) and 30 days old (n = 5) foals were examined for the expression of CD9, SP-A, and SP-D with immunohistology and Western blots. Western blot data showed significant increase in the...
Effectiveness of ivermectin in the treatment of equine Parascaris equorum and Oxyuris equi infections.
   March 17, 2026  
Fifteen horses harboring naturally acquired, patent Parascaris equorum and Oxyuris equi infections were equally allotted to 3 treatment groups given (1) injectable vehicle; (2) injectable ivermectin at the dose rate of 200 microgram/kg of body weight; and (3) injectable ivermectin at the rate of 300 microgram/kg. All treatments were given IM in the neck. All animals were killed 14 days after treatment and examined for the targeted nematodes. Regardless of dose rate, ivermectin proved 100% effective in the removal of adult O equi and P equorum infections. Levels of immature P equorum were decre...
Complement factor B expression profile in a spontaneous uveitis model.
   March 17, 2026  
Equine recurrent uveitis serves as a spontaneous model for human autoimmune uveitis. Unpredictable relapses and ongoing inflammation in the eyes of diseased horses as well as in humans lead to destruction of the retina and finally result in blindness. However, the molecular mechanisms leading to inflammation and retinal degeneration are not well understood. An initial screening for differentially regulated proteins in sera of uveitic cases compared to healthy controls revealed an increase of the alternative pathway complement component factor B in ERU cases. To determine the activation status ...
1 87 88 89